May 08, 2026 a 01:00 pm
LLY: Analysts Ratings - Eli Lilly and Company
Eli Lilly and Company, a leader in the pharmaceutical industry, has been the focus of numerous analyst ratings over the past months. With a steady pipeline of innovative drugs and strategic collaborations, the company's stock (Ticker: LLY) has seen varying sentiment levels from financial analysts. The firm's pharmaceutical portfolio, encompassing diabetes care and innovative cancer treatments, remains a strong hold in the healthcare sector.
Historical Stock Grades
The current analyst ratings for Eli Lilly and Company showcase a balanced perspective with notable confidence in the company's market positioning. A significant portion of the ratings remains in the 'Buy' category, indicating optimistic expectations for stock performance.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 18 | |
| Hold | 6 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over the past year, the overall sentiment concerning Eli Lilly's stock has shown minor fluctuations, with 'Buy' and 'Hold' ratings remaining relatively stable. This consistency indicates a persistent belief in the company's growth potential, albeit with some caution reflected through 'Hold' ratings.
- The number of 'Strong Buy' ratings has experienced slight variations, peaking in mid-2025 and then stabilizing.
- 'Buy' ratings remain predominant, suggesting sustained optimism among analysts.
- 'Hold' ratings continue to rise gradually, indicating some level of market caution.
Percentage Trends
The percentage distribution of analyst ratings for Eli Lilly shows a pronounced tendency towards buying recommendations, though a marginal increase in 'Hold' ratings suggests a more nuanced perspective emerging over time.
- From mid-2025, the percentage of 'Strong Buy' ratings decreased slightly, countered by a lapse in 'Buy' percentages.
- 'Hold' percentage increased, signaling enhanced prudent stances by investors.
- Overall, the slight increase in 'Hold' ratings may signal growing market caution or skepticism towards short-term gains.
Latest Analyst Recommendations
Recent analyst recommendations for LLY reflect an ongoing supportive sentiment with maintenance positions constituting the majority. Stability in these ratings suggests sustained belief in the company’s long-term prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-05-05 | Buy | Buy | Guggenheim |
| 2026-05-05 | Overweight | Overweight | Barclays |
| 2026-05-04 | Outperform | Outperform | Wolfe Research |
| 2026-05-01 | Overweight | Overweight | Cantor Fitzgerald |
| 2026-04-22 | Buy | Buy | Guggenheim |
Analyst Recommendations with Change of Opinion
A notable shift in analyst opinion reveals changes in sentiment, with some downgrades and upgrades indicating dynamic market interpretations of Eli Lilly's strategic direction.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-17 | Reduce | Hold | HSBC |
| 2026-02-10 | Buy | Hold | Freedom Broker |
| 2025-11-10 | Hold | Buy | Freedom Capital Markets |
| 2025-11-10 | Outperform | Market Perform | Leerink Partners |
| 2025-11-10 | Hold | Buy | Freedom Broker |
Interpretation
The constant re-evaluation of Eli Lilly's market stance by analysts suggests a healthy, albeit cautious confidence in its future trajectory. The balance between 'Buy' and 'Hold' ratings reflects a sentiment of stability with underlying vigilance. While occasional downgrades pinpoint isolated concerns, these are often matched by affirmations of strong performance through upgrades.
Conclusion
Eli Lilly and Company represents a compelling opportunity within the pharmaceutical sector, supported by robust analyst ratings that largely advocate for purchase holdings. Despite some emerging cautious tones through increased 'Hold' positions, the stock remains an attractive long-term proposition due to its innovative drug portfolio and strategic alliances. By maintaining a watchful eye on any shifts in analyst opinion, investors can make informed decisions in managing their positions in LLY. Overall, the analyst sentiment remains broadly confident, allowing for continued trust in Eli Lilly’s market performance.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years